TPST insider filings
Tempest Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen TPST transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 5 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Frederick John W. — Director | 2 | — | — | 1 |
| Smith Nancy Freda — Director | 2 | — | — | 1 |
| Horn-Warnock Stephanie — CFO, Treasurer, & Corp Sec. | 1 | — | — | — |
Recent insider filings — Tempest Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 3 | Horn-Warnock Stephanie — CFO, Treasurer, & Corp Sec. | Holdings only — no transactions reported | EDGAR |
| 2026-11-02 | 3 | Frederick John W. — Director | Holdings only — no transactions reported | EDGAR |
| 2026-11-02 | 4 | Frederick John W. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-10-02 | 3 | Smith Nancy Freda — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-02 | 4 | Smith Nancy Freda — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Angel Matthew — CEO and President, Director, 10% owner | Purchase (P): 231,482 @ $2.16 · Purchase (P): 231,482 (derivative) · Purchase (P): 231,482 (derivative) | EDGAR |
| 2026-06-17 | 4 | Yee John D. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Richey William Drake — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Trojanowski Justin — Corporate Controller | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Maestas Nicholas — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-03-25 | 4 | Angel Matthew — CEO and President, Director, 10% owner | Purchase (P): 231,482 @ $2.16 | EDGAR |
| 2026-02-06 | 4 | Angel Matthew — CEO and President, Director, 10% owner | Grant/award (A): 269,621 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Simantov Ronit — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | RAAB MICHAEL — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | NICHOL GEOFFREY — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Pellizzari Christine A — Director | Grant/award (A): 1,230 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Maestas Nicholas — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Trojanowski Justin — Corporate Controller | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Brady Stephen R — President and CEO, Director | Grant/award (A): 550,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Whiting Samuel — Chief Medical Officer | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2024-08-12 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Ventures IV, LLC — 10% owner Versant Venture Capital IV, L.P. — 10% owner Versant Side Fund IV, L.P. — 10% owner | Sale (S): 400,000 @ $1.35 · Sale (S): 387,999 @ $1.10 | EDGAR |
| 2024-07-08 | 4 | Brady Stephen R — President and CEO, Director | Purchase (P): 35,000 @ $2.11 | EDGAR |
| 2024-07-03 | 4 | Whiting Samuel — Chief Medical Officer | Purchase (P): 4,672 @ $2.13 | EDGAR |
| 2024-07-02 | 4 | Trojanowski Justin — Corporate Controller | Purchase (P): 7,500 @ $2.16 | EDGAR |
| 2024-06-14 | 4 | Simantov Ronit — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | RAAB MICHAEL — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | NICHOL GEOFFREY — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Pellizzari Christine A — Director | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Brady Stephen R — President and CEO, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Whiting Samuel — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Trojanowski Justin — Principal Accounting Officer | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Maestas Nicholas — VP of Strategy and Finance | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-10-13 | 4 | Brady Stephen R — President and CEO, Director | Grant/award (A): 725,000 (derivative) @ $0 | EDGAR |
| 2023-10-13 | 4 | Trojanowski Justin — Corporate Controller | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2023-10-13 | 4 | Whiting Samuel — Chief Medical Officer | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2023-10-13 | 4 | Maestas Nicholas — VP of Strategy and Finance | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Simantov Ronit — Director | Grant/award (A): 8,200 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | RAAB MICHAEL — Director | Grant/award (A): 8,200 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | NICHOL GEOFFREY — Director | Grant/award (A): 8,200 (derivative) @ $0 | EDGAR |
| 2023-06-20 | 4 | Pellizzari Christine A — Director | Grant/award (A): 8,200 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Whiting Samuel — Chief Medical Officer | Grant/award (A): 69,700 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Dubensky Thomas W. — President, Director | Grant/award (A): 102,700 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Brady Stephen R — Chief Executive Officer, Director | Grant/award (A): 177,300 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Maestas Nicholas — VP of Strategy and Finance | Grant/award (A): 38,425 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Trojanowski Justin — Corporate Controller | Grant/award (A): 20,300 (derivative) @ $0 | EDGAR |
| 2022-10-04 | 4 | Trojanowski Justin — Corporate Controller | Grant/award (A): 2,500 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Simantov Ronit — Director | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | RAAB MICHAEL — Director | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | NICHOL GEOFFREY — Director | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Pellizzari Christine A — Director | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — Tempest Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-20 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-11-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-11-06 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-10-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-10-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-10-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Tempest Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-298498 (S-1) — latest: Initial registration (S-1), filed 2026-08-21
GET https://api.filingpulse.io/v1/insider-trades?ticker=TPST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs